GC Biopharmas Alyglo added to U.S. insurance ... > 경제기사 | economics

South Korea’s GC Biopharma Corp. announced on Tuesday that its primary immune deficiency treatment, Alyglo, has been added to the formularies of three major U.S. health insurance companies.

Alyglo is a 10 percent intravenous immunoglobulin IVIG treatment that received U.S. Food and Drug Administration FDA approval in December last year.


The inclusion of Alyglo in these formularies is part of GC Pharma’s broader efforts to penetrate the U.S. market. The company previously signed contracts with six U.S. pharmacy benefit managers PBMs and group purchasing organizations GPOs, including Express Scripts Inc. ESI, one of the three largest PBMs in the country.

Additionally, partnerships with specialty pharmacies have been finalized.

Alyglo now has access to 80 percent of private insurance policyholders in the U.S., reaching its original market penetration goal.

▶ 결국 안세영이 맞았다…선수 후원금까지 빼돌린 ‘아사리판’ 배드민턴협회

▶ “피같은 돈 열심히 냈더니”...노인 60만명, 국민연금 받는다고 기초연금 깎여

▶ 오늘의 운세 2024년 9월 11일 水음력 8월 9일

▶ “이런 자식 가진 부모는 얼마나 좋을까”…세 쌍둥이 명문대 동시합격 화제

▶ “공개 연애 한달만에 결혼 발표”…박소영, 예비신랑은 전직 프로야구 선수